According to Cartesian Therapeutics Descartes-15 includes technology intended to provide it with predictable and controllable pharmacokinetics and enhanced CAR stability. #mmsm #MultipleMyeloma #celltherapy Read more: https://lnkd.in/emvPsETx
CGTLive’s Post
More Relevant Posts
-
mRNA-based therapeutics are revolutionizing medicine, but before their release into the clinic it is critical that they receive comprehensive characterization to evaluate safety and efficacy. In Eclipsebio’s latest eBlog we review several approaches for profiling key aspects of mRNA drug products. Follow the link to read more: https://lnkd.in/gPjjw3Yd • • • • #therapeutics #mRNA #rnatherapeutics #biotechnology
-
-
I will read this.
In the run up to the World Trade Organization #MC13 our new research paper discusses why the #TRIPSdecision of #MC12 should be extended to #COVID19 therapeutics & diagnostics, how #TRIPSflexibilities can be used optimally in a pandemic, and how the process of decision making on a waiver can be improved: https://lnkd.in/gMxPJXjM Nirmalya Syam Muhammad Abbas, PhD
-
-
Benign Prostatic Hyperplasia Therapeutics Market Positioning Strategy in 2024: Identifying Unique Value Propositions https://lnkd.in/eUDv4ZCN #marketanalysis #marketresearch #marketresearchreports #businessintelligence
-
In the run up to the World Trade Organization #MC13 our new research paper discusses why the #TRIPSdecision of #MC12 should be extended to #COVID19 therapeutics & diagnostics, how #TRIPSflexibilities can be used optimally in a pandemic, and how the process of decision making on a waiver can be improved: https://lnkd.in/gMxPJXjM Nirmalya Syam Muhammad Abbas, PhD
-
-
🎯 Precision in Therapeutics Release! 🎯 We're redefining drug delivery with controlled, local, and on-demand releases of therapeutics directly at the epicardium. Discover how we're enhancing the healing process for heart tissue. #DrugDelivery #CardiacHealth #REBORNProject
-
-
Interested in the intersection of research and therapeutic development? Our latest case study explores the Functional Assessment of Properdin and methods to assess AP-modulation, providing valuable insights into the evolving landscape of complement therapeutics. https://hubs.ly/Q02CcWvG0 #ComplementingLifeScience #AnswersinLifeScience #Complementsystem #Complementbiology #AlternativePathway #Properdin #drugdevelopment
-
-
Interested in learning about the importance of extracellular vesicles (EVs) in intercellular communication and therapeutic applications? Read our full article: https://lnkd.in/gSgpedfS EVs promise advancements in diagnostics, therapeutics, and vaccine delivery due to their abundance and natural role as carriers. #extracellularvesicles #diagnostics #therapeutics
-
-
MAX BioPharma's Oxysterol Therapeutics Platform technology continues to provide insights into the potential of our drug candidates in additional disease areas, most recently in cystic fibrosis (CF). CF is a rare but devastating disorder that is often diagnosed in childhood and worsens with time. Unfortunately, individuals with CF are of gravely poor health, and although some of the new CFTR modulators when administered in a triple combination have had some clinical benefits, their effects on improving quality of life have been quite modest. We hope that we can provide some hope with our drug candidates that have potent anti-inflammatory and anti-fibrotic activities and are showing benefits in preclinical models of CF. #Oxysterol #Cysticfibrosis #Inflammation #CFF #Metaba #MAXBIOPHARMA
-
-
Co-Founder - Global Project Leader - Life Sciences Subject Matter Expert - Engineering and Manufacturing
The #radiopharmaceutical industry is grappling with #supplychain challenges due to shortages of the rare isotope #Actinium225, essential for advanced #cancertreatments. Ac-225, crucial for #radioligandtherapies, is in limited supply as it is not naturally occurring and primarily sourced from dwindling Cold War-era stockpiles. Companies like TerraPower are pioneering production, using decaying Thorium-229 to extract Ac-225, aiming to produce doses for 500,000 treatments annually by 2030. However, some still question whether this will meet market demand and as a result are exploring alternatives like Lead-212, which offers a different radiation profile but is more readily available. Despite these challenges, the relentless pursuit of innovative solutions and strategic collaborations within the industry fuels optimism. By overcoming these supply hurdles, we are on the cusp of transforming cancer care and delivering hope to millions of patients worldwide. Find the full article in the comments below:
-
